Cadonilimab (PD-1/CTLA-4) in combination with lenvatinib in unresectable hepatocellular carcinoma (uHCC): A retrospective real-world study
This study demonstrated the efficacy and safety of this combination, potentially improving outcomes as a first-line therapy, and offering a novel therapeutic approach for advanced HCC.
Authors
- Jie Liu (ORCID: https://orcid.org/0009-0001-0952-632X)
- Kaiyan Su
- Xiao Hu (ORCID: https://orcid.org/0000-0003-1128-4099)
- Guosheng Yuan (ORCID: https://orcid.org/0000-0002-2118-4553)
- Yongru Chen (ORCID: https://orcid.org/0000-0001-6134-3355)
- Jinzhang Chen (ORCID: https://orcid.org/0000-0003-4964-2218)
- Yangfeng Du
- Junjie Wang (ORCID: https://orcid.org/0000-0003-4864-6559)
- Qi Li (ORCID: https://orcid.org/0000-0003-4780-3831)
- Yan Wang (ORCID: https://orcid.org/0000-0002-6511-1495)
- Wenli Li (ORCID: https://orcid.org/0000-0002-3532-6444)
- Qiong Deng
- Peilin Zhu
- Rong Li (ORCID: https://orcid.org/0009-0000-9591-7214)
- Mengya Zang
Institutions
- Central South University (CN)
- Second Affiliated Hospital of Guangzhou Medical University (CN)
- Ganzhou People's Hospital (CN)
- Nanfang Hospital (CN)
- The First People's Hospital of Changde (CN)
- Bio-Medical Science (South Korea) (KR)
- Southern Medical University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Heliyon
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1016/j.heliyon.2024.e37616
- Citations
- 7
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.59
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Guangdong Medical Research Foundation
- National Key Research and Development Program of China